{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T07:33:00Z","timestamp":1767857580939,"version":"3.49.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPG8C1291"],"award-info":[{"award-number":["CMRPG8C1291"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPG8C1051"],"award-info":[{"award-number":["CMRPG8C1051"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.schres.2017.03.041","type":"journal-article","created":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T21:19:31Z","timestamp":1490735971000},"page":"391-397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Increased serum levels of cysteine in patients with schizophrenia: A potential marker of cognitive function preservation"],"prefix":"10.1016","volume":"192","author":[{"given":"Liang-Jen","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pao-Yen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Ching","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Ting","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Chih","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mian-Yoon","family":"Chong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chieh-Hsin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Fa","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2017.03.041_bb0005","series-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR)","author":"American Psychiatric Association","year":"2000"},{"issue":"4","key":"10.1016\/j.schres.2017.03.041_bb0010","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/0269881103174013","article-title":"The Barnes Akathisia Rating Scale\u2014revisited","volume":"17","author":"Barnes","year":"2003","journal-title":"J. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2017.03.041_bb0015","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.biopsych.2008.03.004","article-title":"N-acetyl cysteine as a glutathione precursor for schizophrenia\u2014a double-blind, randomized, placebo-controlled trial","volume":"64","author":"Berk","year":"2008","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2017.03.041_bb0020","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.tips.2013.01.001","article-title":"The promise of N-acetylcysteine in neuropsychiatry","volume":"34","author":"Berk","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.schres.2017.03.041_bb0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/WOX.0b013e3182439613","article-title":"Oxidative stress and antioxidant defense","volume":"5","author":"Birben","year":"2012","journal-title":"World Allergy Organ. J."},{"key":"10.1016\/j.schres.2017.03.041_bb0030","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.semcdb.2015.03.008","article-title":"Cysteine string protein (CSP) and its role in preventing neurodegeneration","volume":"40","author":"Burgoyne","year":"2015","journal-title":"Semin. Cell Dev. Biol."},{"issue":"12","key":"10.1016\/j.schres.2017.03.041_bb0035","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.tics.2015.09.009","article-title":"How schizophrenia develops: cognitive and brain mechanisms underlying onset of psychosis","volume":"19","author":"Cannon","year":"2015","journal-title":"Trends Cogn. Sci."},{"issue":"2","key":"10.1016\/j.schres.2017.03.041_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029341","article-title":"Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial","volume":"7","author":"Carmeli","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.schres.2017.03.041_bb0045","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/path.4659","article-title":"Cysteine and hydrogen sulphide in the regulation of metabolism: insights from genetics and pharmacology","volume":"238","author":"Carter","year":"2016","journal-title":"J. Pathol."},{"key":"10.1016\/j.schres.2017.03.041_bb0050","first-page":"357","article-title":"Global economic burden of schizophrenia: a systematic review","volume":"12","author":"Chong","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"5","key":"10.1016\/j.schres.2017.03.041_bb0055","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/j.1440-1614.2004.01364.x","article-title":"Quality of life and related risk factors in a Taiwanese village population 21 months after an earthquake","volume":"38","author":"Chou","year":"2004","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2017.03.041_bb0060","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1503\/jpn.100057","article-title":"N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action","volume":"36","author":"Dean","year":"2011","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.schres.2017.03.041_bb0065","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.neubiorev.2015.04.015","article-title":"Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review","volume":"55","author":"Deepmala","year":"2015","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"4","key":"10.1016\/j.schres.2017.03.041_bb0070","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1515\/BC.2003.059","article-title":"Glutathione pathways in the brain","volume":"384","author":"Dringen","year":"2003","journal-title":"Biol. Chem."},{"issue":"3","key":"10.1016\/j.schres.2017.03.041_bb0075","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1474-9726.2007.00294.x","article-title":"Oxidative stress and aberrant signaling in aging and cognitive decline","volume":"6","author":"Droge","year":"2007","journal-title":"Aging Cell"},{"issue":"3","key":"10.1016\/j.schres.2017.03.041_bb0080","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/ajcn\/88.3.738","article-title":"Homocysteine, cysteine, and body composition in the Hordaland Homocysteine Study: does cysteine link amino acid and lipid metabolism?","volume":"88","author":"Elshorbagy","year":"2008","journal-title":"Am. J. Clin. Nutr."},{"issue":"9","key":"10.1016\/j.schres.2017.03.041_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044166","article-title":"The association of cysteine with obesity, inflammatory cytokines and insulin resistance in Hispanic children and adolescents","volume":"7","author":"Elshorbagy","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.schres.2017.03.041_bb0090","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/WNF.0000000000000001","article-title":"N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"36","author":"Farokhnia","year":"2013","journal-title":"Clin. Neuropharmacol."},{"issue":"5","key":"10.1016\/j.schres.2017.03.041_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010883","article-title":"Alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population","volume":"5","author":"Gall","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.schres.2017.03.041_bb0100","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12888-014-0268-x","article-title":"Oxidative stress in schizophrenia: a case-control study on the effects on social cognition and neurocognition","volume":"14","author":"Gonzalez-Liencres","year":"2014","journal-title":"BMC Psychiatry"},{"issue":"42","key":"10.1016\/j.schres.2017.03.041_bb0105","doi-asserted-by":"crossref","first-page":"16621","DOI":"10.1073\/pnas.0706778104","article-title":"Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence","volume":"104","author":"Gysin","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.schres.2017.03.041_bb0110","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1089\/ars.2010.3463","article-title":"Genetic dysregulation of glutathione synthesis predicts alteration of plasma thiol redox status in schizophrenia","volume":"15","author":"Gysin","year":"2011","journal-title":"Antioxid. Redox Signal."},{"issue":"1","key":"10.1016\/j.schres.2017.03.041_bb0115","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1440-1819.2010.02157.x","article-title":"No association between glutathione-synthesis-related genes and Japanese schizophrenia","volume":"65","author":"Hanzawa","year":"2011","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2017.03.041_bb0120","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jchromb.2013.12.041","article-title":"Analytical methods involving separation techniques for determination of low-molecular-weight biothiols in human plasma and blood","volume":"964","author":"Isokawa","year":"2014","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"6","key":"10.1016\/j.schres.2017.03.041_bb0125","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/schbul\/sbs130","article-title":"A systematic review and meta-analysis of recovery in schizophrenia","volume":"39","author":"Jaaskelainen","year":"2013","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2017.03.041_bb0130","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2017.03.041_bb0135","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0165-1781(88)90038-8","article-title":"Reliability and validity of the positive and negative syndrome scale for schizophrenics","volume":"23","author":"Kay","year":"1988","journal-title":"Psychiatry Res."},{"issue":"2\u20133","key":"10.1016\/j.schres.2017.03.041_bb0140","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.schres.2003.09.011","article-title":"The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery","volume":"68","author":"Keefe","year":"2004","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2017.03.041_bb0145","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1176\/appi.ajp.163.3.426","article-title":"The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity","volume":"163","author":"Keefe","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2017.03.041_bb0150","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.schres.2008.03.024","article-title":"Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS)","volume":"102","author":"Keefe","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2017.03.041_bb0155","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1196\/annals.1432.022","article-title":"Glutamate cysteine ligase modifier (GCLM) subunit gene is not associated with methamphetamine-use disorder or schizophrenia in the Japanese population","volume":"1139","author":"Kishi","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.schres.2017.03.041_bb0160","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.schres.2015.06.022","article-title":"Implications for reactive oxygen species in schizophrenia pathogenesis","volume":"176","author":"Koga","year":"2016","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2017.03.041_bb0165","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1176\/appi.ps.54.2.249","article-title":"Prevalence of psychiatric disorders among bereaved survivors of a disastrous earthquake in taiwan","volume":"54","author":"Kuo","year":"2003","journal-title":"Psychiatr. Serv."},{"issue":"6","key":"10.1016\/j.schres.2017.03.041_bb0170","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00005053-198506000-00005","article-title":"Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale","volume":"173","author":"Lane","year":"1985","journal-title":"J. Nerv. Ment. Dis."},{"issue":"4","key":"10.1016\/j.schres.2017.03.041_bb0175","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.pnpbp.2011.03.001","article-title":"Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia","volume":"35","author":"Li","year":"2011","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2017.03.041_bb0180","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.schres.2009.12.017","article-title":"Genetic analysis of glutamate cysteine ligase modifier (GCLM) gene and schizophrenia in Han Chinese","volume":"119","author":"Ma","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2017.03.041_bb0185","article-title":"Antioxidant treatments for schizophrenia","volume":"2","author":"Magalhaes","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"issue":"7","key":"10.1016\/j.schres.2017.03.041_bb0190","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0165-6147(02)02060-6","article-title":"Cerebral cystine uptake: a tale of two transporters","volume":"23","author":"McBean","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"issue":"11","key":"10.1016\/j.schres.2017.03.041_bb0195","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1038\/npp.2011.109","article-title":"N-acetyl cysteine treatment rescues cognitive deficits induced by mitochondrial dysfunction in G72\/G30 transgenic mice","volume":"36","author":"Otte","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"10039","key":"10.1016\/j.schres.2017.03.041_bb0200","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","article-title":"Schizophrenia","volume":"388","author":"Owen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2017.03.041_bb0205","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.pnpbp.2012.10.017","article-title":"Antioxidants as potential therapeutics for neuropsychiatric disorders","volume":"46","author":"Pandya","year":"2013","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2017.03.041_bb0210","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pnpbp.2014.10.002","article-title":"Towards stage specific treatments: effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia","volume":"57","author":"Rapado-Castro","year":"2015","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2017.03.041_bb0215","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1016\/j.bbagen.2013.04.016","article-title":"The chemistry and biological activities of N-acetylcysteine","volume":"1830","author":"Samuni","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"issue":"Suppl. 20","key":"10.1016\/j.schres.2017.03.041_bb0220","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2017.03.041_bb0225","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"6 Suppl","key":"10.1016\/j.schres.2017.03.041_bb0230","doi-asserted-by":"crossref","first-page":"1652S","DOI":"10.1093\/jn\/136.6.1652S","article-title":"Mammalian cysteine metabolism: new insights into regulation of cysteine metabolism","volume":"136","author":"Stipanuk","year":"2006","journal-title":"J. Nutr."},{"issue":"3","key":"10.1016\/j.schres.2017.03.041_bb0235","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1086\/507566","article-title":"Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene","volume":"79","author":"Tosic","year":"2006","journal-title":"Am. J. Hum. Genet."},{"issue":"10","key":"10.1016\/j.schres.2017.03.041_bb0240","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jnutbio.2014.05.004","article-title":"Food-derived opioid peptides inhibit cysteine uptake with redox and epigenetic consequences","volume":"25","author":"Trivedi","year":"2014","journal-title":"J. Nutr. Biochem."},{"issue":"3","key":"10.1016\/j.schres.2017.03.041_bb0245","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.psychres.2013.01.023","article-title":"Changes in oxidative stress markers in patients with schizophrenia: the effect of antipsychotic drugs","volume":"209","author":"Tsai","year":"2013","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.schres.2017.03.041_bb0250","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/157015909787602823","article-title":"Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options","volume":"7","author":"Uttara","year":"2009","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.schres.2017.03.041_bb0255","first-page":"1","article-title":"The Chinese version of the Brief Assessment of Cognition in Schizophrenia: data of a large-scale Mandarin-speaking population","author":"Wang","year":"2016","journal-title":"Arch. Clin. Neuropsychol."},{"key":"10.1016\/j.schres.2017.03.041_bb0260","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.2147\/NDT.S118110","article-title":"Validation of the Chinese version of Brief Assessment of Cognition in Schizophrenia","volume":"12","author":"Wang","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"5","key":"10.1016\/j.schres.2017.03.041_bb0270","doi-asserted-by":"crossref","first-page":"396","DOI":"10.47102\/annals-acadmedsg.V38N5p396","article-title":"Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress","volume":"38","author":"Wood","year":"2009","journal-title":"Ann. Acad. Med. Singap."},{"issue":"3","key":"10.1016\/j.schres.2017.03.041_bb0275","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/jn\/134.3.489","article-title":"Glutathione metabolism and its implications for health","volume":"134","author":"Wu","year":"2004","journal-title":"J. Nutr."},{"key":"10.1016\/j.schres.2017.03.041_bb0280","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.pnpbp.2013.02.015","article-title":"Free radicals, antioxidant defense systems, and schizophrenia","volume":"46","author":"Wu","year":"2013","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2017.03.041_bb0285","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.schres.2013.11.010","article-title":"Cognition impairment in schizophrenia patients with tardive dyskinesia: association with plasma superoxide dismutase activity","volume":"152","author":"Wu","year":"2014","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2017.03.041_bb0290","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/mp.2011.131","article-title":"Potential metabolite markers of schizophrenia","volume":"18","author":"Yang","year":"2013","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2017.03.041_bb0295","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/mnfr.201500031","article-title":"l-Cysteine metabolism and its nutritional implications","volume":"60","author":"Yin","year":"2016","journal-title":"Mol. Nutr. Food Res."},{"issue":"4","key":"10.1016\/j.schres.2017.03.041_bb0300","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/schbul\/sbv221","article-title":"Working memory in unaffected relatives of patients with schizophrenia: a meta-analysis of functional magnetic resonance imaging studies","volume":"42","author":"Zhang","year":"2016","journal-title":"Schizophr. Bull."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417301810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417301810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:29:37Z","timestamp":1760297377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996417301810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":59,"alternative-id":["S0920996417301810"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2017.03.041","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased serum levels of cysteine in patients with schizophrenia: A potential marker of cognitive function preservation","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2017.03.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}